StockData
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) company profile

SHPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 24, 2026Score 5/30
$4.53−0.23 (-4.83%)

Close on Nov 13, 2026Market cap $4.54MP/E –Yield –

About Shuttle Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Shuttle Pharmaceuticals Holdings, Inc. operates as a pharmaceutical software and drug discovery enterprise centered around Molecule.ai, an artificial intelligence platform acquired in November 2025. The company previously developed clinical-stage therapeutic candidates, notably Ropidoxuridine, prior to initiating a wind-down of its clinical trials. Molecule.ai integrates a unified inference engine, an API-first framework, and modular predictive models to support molecular property prediction, multi-compound comparative analysis, and structured scientific reasoning. These software solutions serve researchers and pharmaceutical research and development teams navigating chemical exploration and early-stage drug design.

The business operates with two full-time employees. Its principal executive offices are situated in Gaithersburg, Maryland, United States. Corporate activities and research infrastructure center around this domestic headquarters location.

Summary of the business section of Shuttle Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Shuttle Pharmaceuticals Holdings, Inc.
Founded
2012
Headquarters
Gaithersburg, MD
Address
401 Professional Drive, Suite 260 20879
Phone
(240) 403-4212
Employees
2, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Forvis Mazars, LLP, Atlanta, Georgia

Stock & identifiers

Ticker
SHPH
Exchange
Nasdaq
IPO date
Aug 31, 2022
Shares outstanding
5M, Sep 21, 2026
Public float
$4.74M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-10 reverse, Jun 11, 2026; 1-for-25 reverse, Jun 16, 2025; 1-for-8 reverse, Aug 13, 2024
SEC CIK
1757499
CUSIP
825693500
ISIN
US8256935003
FIGI
BBG017Z2NFJ1
Share class FIGI
BBG017Z2NGC6
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ryan TrasoliniCo-Chief Executive Officer–
Yuying LiangChief Financial Officer–
Timothy J. LorberChief Financial Officer227,635
Chris CooperInterim Co-CEO–
Angel LirianoDirector0
Arachchige Sachin Eranga PathigodaDirector0
Adam V. ChambersDirector0
Steven M. RichardsDirector210,004
Joseph TungDirector184,162
George ScorsisDirector184,162
Oleh NabytDirector184,162
Joshua SchaferDirector210,004
Milton BrownDirector346,617

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 31, 2022
Offer price
$8.13
Securities offered
1,225,888
Gross proceeds
$9.96M
Exchange
Nasdaq
First trading day
Aug 31, 2022
First-day close
$38.48+373.6%
Lock-up ends (est.)
Feb 27, 2023

“The units are being offered at an assumed combined public offering price of $8.125 per unit and a combined effective offering price of $8.115 per share of common stock and an offering price of $0.01 for each warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of the date of this Annual Report, we have two full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 6, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 22, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 28, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 17, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 17, 2026Late filingNotification of late filing
May 7, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 26, 2025Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 17, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 13, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 7, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 13, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 26, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 13, 2024Late filingNotification of late filing
Mar 5, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 7, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 26, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2023Late filingNotification of late filing
Mar 22, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 31, 2022IPOInitial public offering priced (424B4 prospectus)
Aug 29, 2022ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?